M. Kulyk & Associates LLC Invests $3.84 Million in Becton, Dickinson and Company $BDX

M. Kulyk & Associates LLC purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 25,381 shares of the medical instruments supplier’s stock, valued at approximately $3,841,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Auto Owners Insurance Co lifted its stake in Becton, Dickinson and Company by 22,225.2% during the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock valued at $790,079,000 after buying an additional 40,528,680 shares in the last quarter. BlackRock Inc. purchased a new position in shares of Becton, Dickinson and Company in the second quarter worth approximately $3,721,533,000. Wellington Management Group LLP raised its holdings in shares of Becton, Dickinson and Company by 9,056.3% during the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after acquiring an additional 5,174,944 shares during the period. Vanguard Group Inc. lifted its position in shares of Becton, Dickinson and Company by 13.0% in the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after acquiring an additional 4,223,149 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its position in shares of Becton, Dickinson and Company by 23,219.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock valued at $769,397,000 after acquiring an additional 4,137,888 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. This represents a 3.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 11,779 shares of company stock valued at $1,974,669 over the last three months. 0.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

BDX has been the topic of several research analyst reports. Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Stifel Nicolaus set a $195.00 target price on Becton, Dickinson and Company in a report on Friday, August 7th. Barclays lifted their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Finally, Bank of America reduced their price objective on Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $185.67.

Becton, Dickinson and Company Stock Down 0.5%

BDX stock opened at $181.17 on Wednesday. The company has a 50 day moving average of $159.06 and a two-hundred day moving average of $161.12. The company has a market cap of $49.92 billion, a price-to-earnings ratio of 54.57, a PEG ratio of 12.93 and a beta of 0.19. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the previous year, the company posted $3.68 EPS. Becton, Dickinson and Company’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be given a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.